Exelixis (EXEL) wins FDA approval for Cabometyx for advanced pancreatic and extra pancreatic neuroendocrine tumors in ...

EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

The iLet bionic pancreas system conferred an average glucose ... to participate in a 4-week open-label crossover trial. There were 20 adults attending a primary care clinic and 20 adults receiving ...

A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of ...

Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...

Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer, as it tries to extend the label for the first-in-class drug beyond its ...

The American designer worked for Tadashi Shoji, Tahari and Perry Ellis among others, and had his own namesake company at one ...